Author |
Year |
Study type |
Sample
size |
Antiplatelets used |
Measurements |
Conclusion |
Bednar et al |
2009 |
Prospective cohort |
40 |
Aspirin |
Platelet
aggregation, 11-dehydro thromboxane B2 |
Aspirin does not inhibit
platelet aggregation sufficiently in early postoperative
days. |
Bednar et al |
2012 |
Prospective cohort |
30 |
Aspirin + Clopidogrel |
Platelet aggregation, 11-dehydro thromboxane B2 |
Aspirin-induced
inhibition of thromboxane B2 production and platelet aggregation is
impaired in the early days of the postoperative period. |
Bollinger et al |
2016 |
Prospective cohort |
304 |
Aspirin |
Platelet
aggregation |
Reduced aspirin responsiveness is not associated with
major adverse events after CABG. |
Brambilla et al |
2010 |
Randomised controlled trial |
56 |
Aspirin |
Platelet aggregation, 11-dehydro thromboxane B2 |
Incidence of
antiplatelet resistance is lower with a higher dosage of
aspirin. |
Gasparovic et al |
2014 |
Randomised controlled trial |
219 |
Aspirin |
Platelet aggregation |
Addition of clopidogrel to aspirin-resistant
patients does not reduce adverse outcomes nor increase
bleeding. |
Hiyasat et al |
2014 |
Prospective cohort |
100 |
Aspirin |
Platelet
aggregation |
Aspirin resistance occurs in a large population of
patients after CABG and is associated with worse
outcomes. |
Kempfert et al |
2009 |
Prospective cohort |
59 |
Aspirin |
Platelet
aggregation |
Aspirin resistance is a transient phenomenon in a large
population of patients undergoing CABG. |
Mannacio et al |
2012 |
Randomised controlled trial |
300 |
Aspirin |
Platelet function assay |
Aspirin resistance is a predictor of vein
graft patency, and dual antiplatelet therapy improves it. |
Nicola et al |
2019 |
Prospective cohort |
250 |
Aspirin |
Platelet
aggregation |
Aspirin effects slightly increase blood loss and the
requirement of allogeneic blood transfusion. |
Petricevic et al |
2013 |
Prospective cohort |
131 |
Aspirin +
Clopidogrel |
Platelet aggregation |
Dose adjustment or dual
antiplatelet therapy should be considered in aspirin-resistant patients
to reduce adverse events. |
Petricevic et al |
2011 |
Prospective cohort |
99 |
Aspirin |
Platelet
aggregation |
Postoperative aspirin administration does not sufficiently
inhibit platelet aggregation in CABG patients. |
Poston et al |
2006 |
Prospective cohort |
225 |
Aspirin |
Platelet
aggregation, 11-dehydro thromboxane B2, whole blood flow cytometry |
Aspirin resistance and compromised endothelial integrity lead to vein
graft failure within a few days after off-pump CABG
surgery. |
Wand et al |
2017 |
Prospective cohort |
400 |
Aspirin |
Platelet
aggregation |
High incidence of perioperative aspirin non-response rate
does not increase 1-year cardiovascular adverse event
rate. |
Wang et al |
2012 |
Prospective cohort |
333 |
Aspirin + Clopidogrel |
Platelet aggregation, 11-dehydro thromboxane B2 |
Aspirin resistance is
a transient phenomenon in the early postoperative period. |
Yilmaz et al |
2005 |
Prospective cohort |
28 |
Aspirin |
Platelet
function assay |
Aspirin resistance is highly prevalent in patients with
late occlusion of vein grafts. |
Youn et al |
2014 |
Prospective cohort |
859 |
Aspirin + Clopidogrel |
Platelet function assay |
High residual platelet activity after
clopidogrel administration is associated with a higher 1-year adverse
event rate. |
Willemsen et al |
2021 |
Prospective cohort |
128 |
Aspirin |
Platelet
function assay |
Aspirin-sensitive patients have more 12-hour blood loss
after CABG. |
Zimmermann et al |
2005 |
Prospective cohort |
29 |
Aspirin |
Platelet
aggregation |
The antiplatelet effect of aspirin is largely impaired
after on-pump, but not off-pump CABG. |